ENO Bio has built an industry-leading and comprehensive mRNA application platform that essentially spans the entire spectrum of mRNA technologies and key components. The company has accumulated a portfolio of over 300 global patents, demonstrating broad and deep coverage of core mRNA fields and critical processes, all supported by complete independent intellectual property rights. The platform's capabilities and product viability have been further validated through product development and clinical recognition by major global regulatory authorities, including the NMPA, FDA, and TGA. ENO Bio's mRNA application technology platform provides a solid foundation for developing high-quality products with strong competitive advantages in the global market.

Through this platform, ENO Bio has advanced seven product candidates with differentiated competitive profiles into the clinical stage or obtained clinical trial approvals, recognized by regulatory agencies. The platform efficiently supports the development and clinical registration of various product candidates, covering areas such as oncology, major infectious diseases, and degenerative diseases.